Pseudomonas Aeruginosa Infection Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Pseudomonas Aeruginosa Infection Treatment Market is segmented by Treatment (Monotherapy, Combination Therapy), Route of Administration and Geography.

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Pseudomonas Aeruginosa is a common encapsulated, Gram-negative, rod-shaped bacterium that can cause disease in humans. P. aeruginosa is a multidrug-resistant pathogen recognized for its ubiquity, its intrinsically advanced antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections such as ventilator-associated pneumonia and various sepsis syndromes.

The prevalence of Hospital Acquired Infections have increased in recent years. As pseudomonas aeruginosa infection is one of the common infections in hospital facility, probability of being diagnosed with Pseudomonas Aeruginosa infection is high. This has led increase in research and development in understanding P. aeruginosa. As a result, many drugs are in pipeline for the treatment of this infection. These factors have helped the growth of the market and are expected to help in the future as well.

However, as stated earlier, P. aeruginosa shows to the ability of drug resistance. As a result, many drug developers, who have limited funds are dissuaded from the market. This factor has been hindering the market growth. 

Scope of the Report

Pseudomonas Aeruginosa Infection Treatment Drugs inhibit the growth of pseudomonas aeruginosa or completely eliminate the bacterium.

By Treatment
Monotherapy
Combination Therapy
By Route of Administration
Nasal
Oral
Intravenous
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Combination Therapy is expected to Dominate the Market

Combination therapy for treatment of P. aeruginosa is administered due to different considerations. First, to cover the known or suspected pathogen while results of identification and susceptibility testing are pending, second, to avoid emergence of resistance during treatment and third, due to possible synergistic activity resulting in better clinical outcome.

Research was published by Nicole Fosse et al., in PLoS One Journal 2018. During the study period, patients with P. aeruginosa bloodstream infections (BSI) were identified. Combination therapy was administered in 42.8% and remaining 57.2% were treated with monotherapy. The research concluded that mortality was lower in patients receiving definite combination therapy, as compared to monotherapy and combination therapy showed good results. 

Due to the benefits of combination therapy over monotherapy, this market is expected to increase in the forecast period.

Pseudomonas Aeruginosa Infection Treatment - 1

North America is Expected to Dominate the Market

As per a report by the Agency for Healthcare Research and Quality, 2019, approximately 1 of every 25 hospitalized patients in the United States have a hospital-acquired infection (HAI). This ratio translated to nearly 650,000 patients contract one of these infections annually. According to the American Association for the Advancement of Science, proportion of patients with a hospital-acquired infection was 7.9% in 2017, in Canadian Hospitals. As pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries.

However, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

 

Pseudomonas Aeruginosa Infection Treatment Market - 2

Competitive Landscape

Majority of the Pseudomonas Aeruginosa Infection Treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Hospital Acquired Infections

      2. 4.2.2 Investment in Research and Drug Discovery for Pseudomonas Aeruginosa

    3. 4.3 Market Restraints

      1. 4.3.1 Drug Resistance Ability of Pseudomonas Aeruginosa

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment

      1. 5.1.1 Monotherapy

      2. 5.1.2 Combination Therapy

    2. 5.2 By Route of Administration

      1. 5.2.1 Nasal

      2. 5.2.2 Oral

      3. 5.2.3 Intravenous

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc. (Allergan plc)

      2. 6.1.2 Teva Pharmaceutical Industries Ltd.

      3. 6.1.3 Pfizer, Inc.

      4. 6.1.4 Lupin Pharmaceuticals, Inc.

      5. 6.1.5 AstraZeneca plc

      6. 6.1.6 Merck & Co., Inc.

      7. 6.1.7 Bristol Myers Squibb Company

      8. 6.1.8 Johnson & Johnson

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pseudomonas Aeruginosa Infection Treatment Market market is studied from 2018 - 2026.

The Pseudomonas Aeruginosa Infection Treatment Market is growing at a CAGR of 4.7% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc, Merck & Co Inc, AbbVie Inc. (Allergan) are the major companies operating in Pseudomonas Aeruginosa Infection Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!